Lamictal TM, Haloperidol Decanoate in Schizophrenia

• Status: Terminated
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effect of lamotrigine augmentation of Haloperidol decanoate in the treatment of Resistant Schizophrenia predominantly by verbal resistant hallucinosis: A randomized, double-blind, placebo-controlled, study.

Nadir A.Aliyev & Zafar N.Aliyev

Central Mental Clinic for Outpatients of Baku city of Azerbaijan Republic

Abstract:

OBJECTIVE: The current paper reports on a double-blind, randomized study of the role of lamotrigine as an augmentation agent to haloperidol decanoate in the treatment of out patient's schizophrenia with verbal resistant hallucinosis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Central Mental Clinic for Outpatients of Baku City
• Treatments: Decanoic acid; Haloperidol; Haloperidol decanoate; Lamotrigine

Criteria

Exclusion Criteria:

• Display an acute systemic medical disorder or a medical disorder requiring frequent changes in medication;

• Display a history of seizures, cerebrovascular disease, structural brain damage, from trauma, focal neurological sings on examination, or evidence of any progressive neurological disorder, substance dependence (except tobacco).

Inclusion Criteria:

• age from 18-60;

• both gender;

• resistant scizophrenia patients;

• previous treatment history;

• verbal resistant hallucinosis.